Skip to main content
OpenTrials
Completed

NCT Number: NCT06623773

Study on Structum® in Adult Patients With Osteoarthritis (TRUST)

Chondroitin sulfate (CS) is a SYSADOA and a natural biomacromolecule belonging to the class of glycosaminoglycans. CS is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans.

To this date, no real-world studies have been conducted to precisely describe the burden associated with OA among patients treated with CS.Therefore, an observational, descriptive, prospective, national study will be conducted to describe the burden associated with OA and the quality of life of patients treated with Structum® in Poland.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Rheumatic Diseases

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Maciej Dołżyński, Bialystok, Poland

Loading trial locations.

About this study

This is an observational, descriptive, national, multicentric, prospective, longitudinal study, which will be conducted over a 6-month follow-up period for each patient. The study will not provide or recommend any specific treatment or procedures.

All patients affected by OA in the knee, for whom Structum® is prescribed in a participating center, will be screened in a consecutive manner for eligibility. The study will focus exclusively on patients with OA in the knee as this is the joint most frequently affected and most easily assessed for OA patients.

Two additional data collections can be anticipated for these patients as part of their standard of care follow-up visits, which will usually occur around 3 and 6 months after the initial study visit.The patient enrolment period is expected to be 6 months, with a total study duration of 12 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients aged 50 to 80 years at inclusion
  • of knee OA (either a patient newly diagnosed [at inclusion] or with history of knee OA) based on at least the following items 1 and/or 2:
  • knee pain lasting for at least 3 months;
  • patient in the active phase of knee OA disease (knee pain score ≥ 40mm at inclusion on the Visual Analog Scale [VAS] 0-100 mm);
  • knee radiographs showing knee joint narrowing and/or osteophytes.
  • Patients who have been prescribed, for the first time or not, Structum®.
  • If patient is taking any NSAIDs or other analgesics, patient could be on stable dose at least one week before inclusion to the study.
  • Patients able to visit the clinic and attend follow-up visits.
  • Patients having signed an informed consent form, according to local regulations.

Exclusion criteria

  • Patients with any ongoing chondroitin sulfate treatment at inclusion or during the last 3 months.
  • plasma (in the last 3 months). No glucocorticoids administration in the last 3 months before inclusion. That does not include NSAIDS, paracetamol and other analgesic medications (e.g. tramadol).
  • Patients with an artificial knee joint, including unilateral.
  • Patients scheduled to undergo knee replacement surgery in the next 6 months.
  • Patients with a severe general condition that prevents them from being included in the study as assessed by the investigator.
  • Patients participating in interventional trials on investigational drugs at the time of inclusion.

Treatment and study plan

chondroitin sulfate

Drug

Chondroitin sulfate (CS) is a natural biomacromolecule belonging to the class of glycosaminoglycans and is an unbranched complex polysaccharide consisting of a repeating disaccharide structure of glucuronic acid and N-acetyl-D-glucosamine [18]. It is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans. Oral bioavailability of CS has been demonstrated [19], and its use for the treatment of OA has been established in animal models [20], as well as in clinical trials [21, 22]. CS, is available as a pharmaceutical grade drug (Structum®), meaning that the product is manufactured under Good Manufacturing Practices (GMP) conditions, and is in excess of 99% purity with no binders, fillers, excipients, dyes, or unknown substances. According to the Instructions for Use (IFU), the recommended posology for Structum® is 500 mg twice daily.

Other names: Structum

Primary outcomes

  1. describe the baseline clinical profile and baseline OA symptom severity (pain, stiffness and function) as assessed by the (WOMAC) questionnaire, for patients with knee OA and treated with Structum®.

    Time frame: baseline

    description at enrollment of Demographics and clinical characteristics of patients with knee OA- description of treatment history- description of knee OA symptm severity per the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC )Questionnaire.

    The total WOMAC score range is from 0-2400, with higher scores indicating worse pain, stiffness, and functional limitations.

Secondary outcomes

  1. Secondary Womac outcomes at 3-months

    Time frame: from baseline to 3 months after baseline

    Mean global score of symptoms severity of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC )Questionnaire.

    The total WOMAC score range is from 0-2400, with higher scores indicating worse pain, stiffness, and functional limitations.

  2. Secondary Womac outcomes at 3-months

    Time frame: from baseline to 3 months after baseline

    Mean score of each dimension of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC )Questionnaire.

    For each dimension, the values scored on each item will be summed to give a dimension score, with pain ranging from 0-500, stiffness 0-200, and physical function 0-1700.

  3. Secondary Womac outcomes at 3-months

    Time frame: from baseline to 3 months after baseline

    Mean difference in symptoms severity score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC )Questionnaire.

  4. Secondary Womac outcomes at 6-months

    Time frame: from baseline to 6 months after baseline

    Mean difference in symptoms severity score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC )Questionnaire.

    The total WOMAC score range is from 0-2400, with higher scores indicating worse pain, stiffness, and functional limitations.

  5. Secondary Womac outcomes at 6-months

    Time frame: from baseline to 6 months after baseline

    Mean score of each dimension of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC )Questionnaire.

    For each dimension, the values scored on each item will be summed to give a dimension score, with pain ranging from 0-500, stiffness 0-200, and physical function 0-1700.

  6. Secondary Womac outcomes at 6-months

    Time frame: from baseline to 6 months after baseline

    Mean global score of symptom severity of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC )Questionnaire.

    The total WOMAC score range is from 0-2400, with higher scores indicating worse pain, stiffness, and functional limitations.

  7. Bone's outcome at baseline

    Time frame: baseline

    Mean global score of the OA burden of the Burden Osteoarthritis New'Scale (BONe'S) The total score range is 0-100 scale. Higher scores represent a heavier burden

  8. Bone's outcome at baseline

    Time frame: baseline

    Mean score of each dimension of the Burden Osteoarthritis New'Scale (BONe'S) Each question (19 questions) of each dimension is evaluated from to 5.

  9. Bone's outcome at 3 months

    Time frame: from baseline to 3 months after baseline

    Mean global score of the OA burden of the Burden Osteoarthritis New'Scale (BONe'S) The total score range is 0-100 scale. Higher scores represent a heavier burden

  10. Bone's outcome at 6 months

    Time frame: from baseline to 6months after baseline

    Mean global score of the OA burden of the Burden Osteoarthritis New'Scale (BONe'S) The total score range is 0-100 scale. Higher scores represent a heavier burden

  11. Bone's outcome at 3 months

    Time frame: from baseline to 3 months after baseline

    Mean score of each dimension of the Burden Osteoarthritis New'Scale (BONe'S) Each question (19 questions) of each dimension is evaluated from to 5.

  12. Bone's outcome at 6 months

    Time frame: from baseline to 6 months after baseline

    Mean score of each dimension of the Burden Osteoarthritis New'Scale (BONe'S) The total score range is 0-100 scale. Higher scores represent a heavier burden

  13. Bone's outcome at 3 months

    Time frame: from baseline to 3 months after baseline

    Mean difference in OA burden scores at 3 months of the Burden Osteoarthritis New'Scale (BONe'S) The total score range is 0-100 scale. Higher scores represent a heavier burden

  14. Bone's outcome at 6 months

    Time frame: from baseline to 6 months after baseline

    Mean difference in OA burden scores at 6 months of the Burden Osteoarthritis New'Scale (BONe'S) The total score range is 0-100 scale. Higher scores represent a heavier burden

  15. SF12 outcome at baseline

    Time frame: baseline

    mean global score of general health of the Short Form Questionnaire (SF12) Scores range from 0 to 100, with higher scores indicating a better physical and mental health functioning.

  16. SF12 outcome at 3 months

    Time frame: from baseline to 3 months after baseline

    mean global score of general health of the Short Form Questionnaire (SF12) Scores range from 0 to 100, with higher scores indicating a better physical and mental health functioning.

  17. SF12 outcome at 6 months

    Time frame: from baseline to 6 months after baseline

    mean global score of general health of the Short Form Questionnaire (SF12) Scores range from 0 to 100, with higher scores indicating a better physical and mental health functioning.

  18. SF12 outcome at baseline

    Time frame: baseline

    mean score of physical and mental dimension of the Short Form Questionnaire (SF12) A special scoring program, accessible via the license purchase of the questionnaire, will be used to analyze this questionnaire by giving a ponderation to each item to result in two different dimension scores.

  19. SF12 outcome at 3 months

    Time frame: from baseline to 3 months after baseline

    mean score of physical and mental dimension of the Short Form Questionnaire (SF12) A special scoring program, accessible via the license purchase of the questionnaire, will be used to analyze this questionnaire by giving a ponderation to each item to result in two different dimension scores

  20. SF12 outcome at baseline at 6 months

    Time frame: from baseline to 6 months

    mean score of physical and mental dimension of the Short Form Questionnaire (SF12) A special scoring program, accessible via the license purchase of the questionnaire, will be used to analyze this questionnaire by giving a ponderation to each item to result in two different dimension scores

  21. Persitence outcomes at 3 months

    Time frame: from baseline to 3 months after baseline

    proportion of patients with ongoing Structum® at 3 months

  22. Persitence outcomes at 6 months

    Time frame: from baseline to 6 months after baseline

    proportion of patients with ongoing Structum® at 6 months

  23. Personal global assessment, after first dose of Structum®, at 3 months

    Time frame: from baseline to 3 months after baseline

    Proportion of patients with a positive assessment of Structum®, as assessed by Structum® treatment satisfaction questionnaire

  24. Personal global assessment, after first dose of Structum®, at 6 months

    Time frame: from baseline to 6 months after baseline

    Proportion of patients with a positive assessment of Structum®, as assessed by Structum® treatment satisfaction questionnaire

Other outcomes

  1. Spearman correlation coefficient and P value for the correlation between the BONe'S questionnaire and the SF-12 questionnaire at inclusion.

    Time frame: baseline

  2. Spearman correlation coefficient and P value for the correlation between the BONe'S questionnaire and the SF-12 questionnaire at 3 months

    Time frame: from baseline to 3 months after baseline

  3. Spearman correlation coefficient and P value for the correlation between the BONe'S questionnaire and the SF-12 questionnaire at 6 months

    Time frame: from baseline to 6 months after baseline

  4. Spearman correlation coefficient and P value for the correlation between the BONe'S questionnaire and the WOMAC questionnaire at inclusion

    Time frame: baseline

  5. Spearman correlation coefficient and P value for the correlation between the BONe'S questionnaire and the WOMAC questionnaire at 3 months

    Time frame: from baseline to 3 months after baseline

  6. Spearman correlation coefficient and P value for the correlation between the BONe'S questionnaire and the WOMAC questionnaire at 6 months.

    Time frame: from baseline to 6 months after baseline

  7. Variables of interest for the assessment of this exploratory outcome will originate from the BONe'S, SF-12 and WOMAC questionnaires

    Time frame: from baseline to 6 months after baseline

    Calculation of the Spearman correlation coefficient at inclusion, 3, and 6 months for the correlation between

    • the BONe'S questionnaire (the independence + interaction & recreation + hygiene & beauty scores) and the SF-12 questionnaire (physical component summary dimension).
    • the BONe'S questionnaire (psychological score) and the SF-12 questionnaire (mental component summary dimension)
    • the global score of the BONe'S questionnaire and the total WOMAC score.

  8. Proportion of patients with changes in the prescription of NSAIDs and other analgesics 6 months before inclusion, at inclusion

    Time frame: baseline

    Description of the proportion of patients with a change in their prescription of NSAIDs and other analgesics 6 months before inclusion, at inclusion, and at 3 and 6 months, with a change being defined as any change of the daily dose of NSAIDs (calculated from the frequency of intake and the dose of each intake)

    • Increased
    • Stable
    • Decreased

  9. Proportion of patients with changes in the prescription of NSAIDs and other analgesics 6 months before inclusion, at 3 months

    Time frame: from baseline to 3 months after baseline

  10. Proportion of patients with changes in the prescription of NSAIDs and other analgesics 6 months before inclusion, at 6 months

    Time frame: from baseline to 6 months after baseline

Sponsors and collaborators

Lead sponsor

Pierre Fabre Medicament

Industry

Registry information

Official study title

Prospective Non-Interventional Study on Structum® in Adult Patients With Osteoarthritis

Acronym: TRUST

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 2, 2024
Registry last updated
Jun 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.